Eli Lilly’s existing October 2024 evaluation agreement with Peptron grants only a non-exclusive, internal R&D license for applying SmartDepot’s ultrasonic spray-dried PLGA microsphere technology to peptide candidates, including GLP-1 agents, and explicitly excludes commercial rights while allowing 30-day termination. The evaluation, extended through October 7, 2026, continues with in-vivo studies and expanded CNS work but has produced no public announcements of technology transfer or binding commercial licensing. Lilly’s parallel pursuit of alternative sustained-release platforms such as Camurus’ FluidCrystal further reduces near-term likelihood of a qualifying deal before the fast-approaching deadline, supporting the market’s strong “No” consensus.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว13% โอกาส
$11,414 ปริมาณ
$11,414 ปริมาณ
Oct 6, 2026
13% โอกาส
$11,414 ปริมาณ
$11,414 ปริมาณ
Oct 6, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing October 2024 evaluation agreement with Peptron grants only a non-exclusive, internal R&D license for applying SmartDepot’s ultrasonic spray-dried PLGA microsphere technology to peptide candidates, including GLP-1 agents, and explicitly excludes commercial rights while allowing 30-day termination. The evaluation, extended through October 7, 2026, continues with in-vivo studies and expanded CNS work but has produced no public announcements of technology transfer or binding commercial licensing. Lilly’s parallel pursuit of alternative sustained-release platforms such as Camurus’ FluidCrystal further reduces near-term likelihood of a qualifying deal before the fast-approaching deadline, supporting the market’s strong “No” consensus.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
ตลาดเปิดเมื่อ: May 5, 2026, 8:02 PM ET
ปริมาณการซื้อขาย
$11,414วันสิ้นสุด
Oct 7, 2026ตลาดเปิดเมื่อ
May 5, 2026, 8:02 PM ETผู้ตัดสินผล
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing October 2024 evaluation agreement with Peptron grants only a non-exclusive, internal R&D license for applying SmartDepot’s ultrasonic spray-dried PLGA microsphere technology to peptide candidates, including GLP-1 agents, and explicitly excludes commercial rights while allowing 30-day termination. The evaluation, extended through October 7, 2026, continues with in-vivo studies and expanded CNS work but has produced no public announcements of technology transfer or binding commercial licensing. Lilly’s parallel pursuit of alternative sustained-release platforms such as Camurus’ FluidCrystal further reduces near-term likelihood of a qualifying deal before the fast-approaching deadline, supporting the market’s strong “No” consensus.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
ปริมาณการซื้อขาย
$11,414วันสิ้นสุด
Oct 7, 2026ตลาดเปิดเมื่อ
May 5, 2026, 8:02 PM ETผู้ตัดสินผล
0x65070BE91...Eli Lilly’s existing October 2024 evaluation agreement with Peptron grants only a non-exclusive, internal R&D license for applying SmartDepot’s ultrasonic spray-dried PLGA microsphere technology to peptide candidates, including GLP-1 agents, and explicitly excludes commercial rights while allowing 30-day termination. The evaluation, extended through October 7, 2026, continues with in-vivo studies and expanded CNS work but has produced no public announcements of technology transfer or binding commercial licensing. Lilly’s parallel pursuit of alternative sustained-release platforms such as Camurus’ FluidCrystal further reduces near-term likelihood of a qualifying deal before the fast-approaching deadline, supporting the market’s strong “No” consensus.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย